|
SATURN研究的意义和近况
迄今唯一探讨EGFR生物标记物与EGFR-TKI维持治疗疗效相关性的前瞻、多中心、随机、双盲、安慰剂对照的III期临床研究, 29个国家和地区,152个研究中心参与。完成入组并在2009年ASCO上作了口头报道。
SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with 1st-line platinum-based chemotherapy in patients with advanced NSCLC
Federico Cappuzzo1, Tudor Ciuleanu2, Lilia Stelmah3, Saulius Cicenas4,
Aleksandra Szczesna5, Erzsebet Juhasz6, Emilio Esteban Gonzalez7,
Olivier Molinier8, Gaelle Klingelschmitt9, Giuseppe Giaccone10, on behalf of the SATURN investigators
1Istituto Clinico Humanitas IRCCS, Rozzano (Milan), Italy; 2Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania; 3Pavlov State Medical University, St Petersburg, Russian Federation; 4Institute of Oncology, Vilnius University, Vilnius, Lithuania; 5Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlic, Otwock, Poland; 6Koranyi National Institute for Pulmonology, Budapest, Hungary; 7Hospital Universitario Central de Asturias, Oviedo, Spain; 8Centre Hospitalier Le Mans, Le Mans, France; 9F. Hoffmann-La Roche Ltd, Basel, Switzerland; 10CCR, National Cancer Institute, NIH, Bethesda, MD
J Clin Oncol 27:7s, 2009 (suppl; abstr 8001) |
|